Pancreatic Cancer Research

ResearcherNational Taiwan UniversityActive in the last 2 years

Ming‐Chu Chang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5108095423. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 4 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 22

  1. PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomics. Co-author DOI 10.1038/s41467-026-69426-9↗
  2. Author Correction: PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomics. Co-author DOI 10.1038/s41467-026-72208-y↗
  3. Correction: SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Co-author DOI 10.1038/s41417-024-00857-6↗
  4. Exosomal miRNA 16-5p/29a-3p from pancreatic cancer induce adipose atrophy by inhibiting adipogenesis and promoting lipolysis. Co-author DOI 10.1016/j.isci.2024.110346↗
  5. SEMA7A-mediated juxtacrine stimulation of IGFBP-3 upregulates IL-17RB at pancreatic cancer invasive front. Co-author DOI 10.1038/s41417-024-00849-6↗
  6. Pancreatic cancer-derived small extracellular vesical ezrin activates fibroblasts to exacerbate cancer metastasis through STAT3 and YAP-1 signaling pathways. Last author DOI 10.1002/1878-0261.13442↗
  7. Characterization of initial key steps of IL-17 receptor B oncogenic signaling for targeted therapy of pancreatic cancer. Co-author DOI 10.1126/scitranslmed.abc2823↗
  8. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, a… Co-author DOI 10.3390/diagnostics11091541↗
  9. Using probe electrospray ionization mass spectrometry and machine learning for detecting pancreatic cancer with high performance. Co-author PMID 32051746↗
  10. Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer. First author DOI 10.1016/j.clnu.2018.02.016↗
  11. High accuracy differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma by immunoglobulin G glycosylation. First author DOI 10.1186/s12014-018-9221-1↗
  12. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer. First author DOI 10.1245/s10434-018-07109-6↗
  13. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-018-3960-0↗
  14. Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma. Co-author PMID 30662811↗
  15. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Co-author PMID 28337383↗
  16. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts L… Co-author DOI 10.1097/md.0000000000003407↗
  17. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2015.248260↗
  18. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels. Co-author DOI 10.1016/j.pan.2014.07.010↗
  19. Comparison and validation of International Consensus Diagnostic Criteria for diagnosis of autoimmune pancreatitis from pancreatic cancer in a Taiwanese cohort. Co-author DOI 10.1136/bmjopen-2014-005900↗
  20. Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v20.i17.5060↗
  21. Screening and early detection of pancreatic cancer in high risk population. Co-author DOI 10.3748/wjg.v20.i9.2358↗
  22. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced… Co-author DOI 10.1016/j.ijrobp.2010.10.034↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yu‐Ting Chang · 19 shared papers, 2014–2026 · strength 2.47
  2. Chun‐Mei Hu · 6 shared papers, 2018–2025 · strength 1.04
  3. Yu‐Wen Tien · 11 shared papers, 2011–2025 · strength 1.04
  4. Hsuan‐Yu Peng · 5 shared papers, 2019–2025 · strength 0.97
  5. Sui-Chih Tien · 4 shared papers, 2023–2025 · strength 0.86
  6. Wen‐Hwa Lee · 6 shared papers, 2016–2024 · strength 0.63
  7. Chun-Mei Hu · 3 shared papers, 2019–2026 · strength 0.61
  8. Y.M. Chen · 4 shared papers, 2018–2025 · strength 0.61
  9. Yung‐Ming Jeng · 5 shared papers, 2016–2023 · strength 0.51
  10. Danni Wu · 2 shared papers, 2026 · strength 0.50
  11. Shih‐Hung Yang · 4 shared papers, 2016–2021 · strength 0.34
  12. Tiffany Ting‐Fang Shih · 3 shared papers, 2018–2021 · strength 0.32
  13. Bang‐Bin Chen · 3 shared papers, 2017–2021 · strength 0.29
  14. Po‐Chin Liang · 4 shared papers, 2014–2019 · strength 0.27
  15. Mei‐Fang Cheng · 3 shared papers, 2016–2021 · strength 0.27
  16. Chih‐Horng Wu · 3 shared papers, 2017–2019 · strength 0.26
  17. I‐Shiow Jan · 3 shared papers, 2014–2017 · strength 0.16
  18. Chih-Kai Chang · 1 shared paper, 2021 · strength 0.14
  19. Ashley Robert Dennison · 1 shared paper, 2020 · strength 0.13
  20. Wen Yuan Chung · 1 shared paper, 2020 · strength 0.13
  21. Sén Takeda · 1 shared paper, 2020 · strength 0.13
  22. Lung‐Hung Tsai · 1 shared paper, 2021 · strength 0.11
  23. Heng‐Hsiung Wu · 1 shared paper, 2021 · strength 0.11
  24. Chia‐Ning Shen · 1 shared paper, 2021 · strength 0.11
  25. Vladimir Konstantinovich Lyadov · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.